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RESTORING STUDY 329
Retraction of biased journal articles
Ymkje Anna de Vries PhD student 1, Erick H Turner associate professor 2, Annelieke M Roest
postdoctoral researcher 1
1University of Groningen, University Medical Centre, Groningen, Netherlands; 2Oregon Health and Science University, Portland, OR, USA
We hope that Le Noury and colleagues’ re-analysis of Study
329 will lead to the long overdue retraction of the 2001 paper.1
Study 329 may be the most infamous example of biased
reporting within psychiatry, but this practice is widespread.We
examined the reporting of antidepressant trials submitted to the
FDA and found that 61% and 44% of negative trials for
depression and anxiety, respectively, remained unpublished.2 3
To compound the problem, most published negative trials were
reported as positive, often because of outcome reporting bias.
For example, our analysis included trial STL-N/S-95-003
(sertraline for social phobia). Amemo in the FDA review stated:
“Since the sponsor acknowledged that this was a negative study
. . . they needed to submit only a summary report.” However,
this trial was published as a success.4 Closer examination shows
that significant results for sertraline were obtained by
dichotomising a combination of scales into response versus
non-response categories. The discrepancy between this article
and the company’s acknowledgement of a negative result is
striking.
Although our papers clearly identified biased articles, none has
since been retracted. Like Study 329, these articles still exist in
the literature, with nothing to alert the unsuspecting reader that
the results are misleading. We therefore encourage journal
editors, drug companies, and authors to retract these
publications. Such an unequivocal stance against biased
reporting will help ensure that the literature is a faithful
representation of the true results.
Competing interests: None declared.
Full response at: www.bmj.com/content/351/bmj.h4320/rr-21.
1 Le Noury J, Nardo JM, Healy D, et al. Restoring Study 329: efficacy and harms of
paroxetine and imipramine in treatment of major depression in adolescence. BMJ
2015;351:h4320. (16 September.)
2 Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant
trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
3 Roest AM, de Jonge P, Williams CD, et al. Reporting bias in clinical trials investigating
the efficacy of second-generation antidepressants in the treatment of anxiety disorders:
a report of 2 meta-analyses. JAMA Psychiatry 2015;72:500-10.
4 Blomhoff S, Haug TT, Hellström K, et al. Randomised controlled general practice trial of
sertraline, exposure therapy and combined treatment in generalised social phobia. Br J
Psychiatry 2001;179:23-30.
Cite this as: BMJ 2015;351:h5497
© BMJ Publishing Group Ltd 2015
y.a.de.vries@umcg.nl
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;351:h5497 doi: 10.1136/bmj.h5497 (Published 21 October 2015) Page 1 of 1
Letters
LETTERS
